Editorial ...............................................................................................................................1
Program ...............................................................................................................................4
Plenární přednášky
prof. Dr. Hans-Ulrich Wittchen ................................................................................................11
prof. Jan Volavka, MD, PhD. ...................................................................................................11
prof. ThDr. Otakar A. Funda, Dr. Theol......................................................................................11
Odborná sympozia
Sympozium Společnosti pro biologickou psychiatrii:
Abnormní pohyby v psychiatrii a neurologii .............................................................................12
Terapeutické implikace klinicko-patologických korelací neurodegenerativních onemocnění ..........13
Antipsychotika .....................................................................................................................14
Personalizovaná léčba psychofarmaky ...................................................................................16
Sympozium České a Slovenské psychiatrické společnosti:
Farmakoterapie psychický poruch – záleží na pohlaví? ............................................................16
EPIGENOM – nové interpretační možnosti genetiky ................................................................18
Antidepresiva ...................................................................................................................... 19
Thymoprofylaktika ................................................................................................................21
Psychofarmaka v sexuologii ..................................................................................................22
Význam endokanabinoidního sytému u psychiatrických poruch a jejich léčení........................... 23
Anxiolytika – od mechanizmu účinku k praxi.......................................................................... 24
Farmakoterapie a psychoterapie – spolu nebo zvlášť?............................................................. 26
Obsedantně kompulzivní porucha – od psychopatologie k léčbě ...............................................28
Ketamin: Léčebné a výzkumné využití v psychiatrii...................................................................29
Možnosti predikce individuálního průběhu schizofrenie .............................................................31
Personalizované přístupy v diagnostice a léčbě Alzheimerovy choroby ..................................... 32
SETKÁNÍ S ODBORNÍKEM
doc. MUDr. Eva Malá, CSc. ..................................................................................................34
prim. MUDr. Michal Maršálek, CSc. .......................................................................................34
prof. MUDr. Cyril Höschl, DrSc., FRCPsych. ......................................................................... 34
PRACOVNÍ SNÍDANĚ ČNPS
Terapeutické monitorování psychofarmak – význam pro klinickou praxi .....................................35
Nový výzkum
Nový výzkum – Preklinický výzkum .......................................................................................37
Nový výzkum – Klinický výzkum I ..........................................................................................39
Nový výzkum – Klinický výzkum II ........................................................................................ 41
Workshopy
Komplexní přístup v léčbě hraniční poruchy osobnosti..............................................................43
Sedmero hlavních hříchů – Závist ...........................................................................................44
Komplexní léčba úzkostných poruch ......................................................................................46
Diferenciální diagnostika a farmakoterapie demencí III ..............................................................48
Neuropsychiatrické omyly, alarmující příběhy z praxe ............................................................. 48
Vývěsková sdělení
Vývěsková sdělení – Preklinické studie ..................................................................................49
Vývěsková sdělení – Klinické studie....................................................................................... 55
Vývěsková sdělení – Cholinergní neurotransmise, léčba Alzheimerovy choroby ..........................64
Firemní sympozia .................................................................................................................70
Jmenný rejstřík ................................................................................................................... 71
CONTENTS
Editorial................................................................................................................................ 1
Programme............................................................................................................................4
PLENARY LECTURES
prof. Dr. Hans-Ulrich Wittchen ...............................................................................................11
prof. Jan Volavka, MD, PhD. ................................................................................................. 11
prof. ThDr. Otakar A. Funda, Dr. Theol. ...................................................................................11
SCIENTIFIC SYMPOSIA
Abnormal movements in psychiatry and neurology
(Symposium of the Society of Biological Psychiatry) ..............................................................12
Clinico-pathological correlations in neurodegenerative dementias
and their treatment implications ............................................................................................13
Antipsychotics ....................................................................................................................14
Personalized treatment with psychotropic drugs .....................................................................16
Pharmacotherapy of psychic disorders – does the gender matter?
(Sympozium of Czech and Slovak Psychiatric Society) ...........................................................16
The role of endocannabinoid system in psychiatric disorder and their treatment .........................18
EPIGENOM – new aspects for interpretation in genetics ..........................................................19
Antidepressants ...................................................................................................................21
Mood stabilizers ..................................................................................................................22
Psychotropic drugs and sexology ..........................................................................................23
Anxiolytics – from the mechanism of action to the practise ......................................................24
Pharmacotherapy and psychotherapy – together or separately .................................................26
Obsessive compulsive disorder – from psychopathology to the treatment ..................................28
Ketamine: Treatment and research use in psychiatry ..............................................................29
Prediction of individual course of schizophrenia – ways and possibilities ...................................31
Personalized approach in diagnostic and treatment of Alzheimer disease .................................32
MEET THE EXPERT
doc. MUDr. Eva Malá, CSc. ..................................................................................................34
prim. MUDr. Michal Maršálek, CSc. .......................................................................................34
prof. MUDr. Cyril Höschl, DrSc., FRCPsych. ..........................................................................34
ČNPS BREAKFAST SYMPOSIA
Therapeutic monitoring of psychotropic drugs – relevance to clinical practise ............................35
NEW RESEARCH
New research – Preclinical research .....................................................................................37
New research – Clinical research I ........................................................................................39
New research – Clinical research II ........................................................................................41
WORKSHOPS
Complex approach to the patients with borderline personality disorder ......................................43
Seven deadly sins – Envy ....................................................................................................44
Complex treatment of anxiety disorders ................................................................................46
Differencial diagnosis and pharmacotherapy of dementias ......................................................48
Neuropsychiatric mistakes – alarming stories from clinical practice......................................... 48
POSTER SESSIONS
Poster sessions – Preclinical research .................................................................................49
Poster sessions – Clinical research ......................................................................................55
Poster sessions – Cholinergic neurotransmission, treatment of Alzheimer disease .................. 64
SPONSORED SATELLITE SYMPOSIA ................................................................................70
NAME INDEX .....................................................................................................................71
